Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$168.54 USD

168.54
3,821,499

+4.53 (2.76%)

Updated May 24, 2024 02:55 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for Feb 27, 2023

by Zacks Equity Research

Companies in The News Are: NVDA, BA, ADBE, MRNA

Kinjel Shah headshot

Pharma Stock Roundup: FDA Updates for SNY, PFE & Others, EU Nod to AZN Cancer Combo

by Kinjel Shah

FDA approves Sanofi's (SNY) Altuviiio and grants a priority tag to Pfizer's (PFE) regulatory applications for pipeline candidates.

Moderna (MRNA) Lags on Q4 Earnings, COVID Jab Sales Down Y/Y

by Zacks Equity Research

Moderna's (MRNA) fourth-quarter earnings and sales miss expectations. Management reiterates guidance to record a minimum of $5 billion from COVID vaccine sales in 2023.

Perion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Perion Network and West Fraser Timber are part of the Zacks Bull and Bear of the Day article.

Moderna (MRNA) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of -22.53% and 0.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More

by Kinjel Shah

Let us look at four drug and biotech companies, MRNA, BHC, ALNY and AGIO, which are gearing up for their earnings release.

Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors focus will likely be on Moderna's (MRNA) pipeline, especially with its late-stage pipeline candidates, when it reports fourth-quarter earnings.

Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $171.48, moving +1.3% from the previous trading session.

Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Moderna (MRNA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RSP

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) four-quarter 2022 earnings and sales beat estimates. VRTX also issues better-than-expected revenue guidance for 2023.

Moderna (MRNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $171.06, moving +0.46% from the previous trading session.

Should Invesco S&P 500 Equal Weight ETF (RSP) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for RSP

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $174.30, marking a -1% move from the previous day.

Moderna (MRNA) RSV Jab For Older Adults Gets FDA Breakthrough Tag

by Zacks Equity Research

Moderna (MRNA) announces that the FDA granted Breakthrough Therapy Designation to its respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345 for the prevention of respiratory disease in older adults.

The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and Novavax

by Zacks Equity Research

Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.

Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised)

by Zacks Equity Research

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy

by Zacks Equity Research

An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.

Moderna (MRNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $193.24, moving +0.09% from the previous trading session.

Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe

by Zacks Equity Research

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Moderna (MRNA) Stock Moves 1.89%: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $193.98, marking a +1.89% move from the previous day.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Donanemab Gets FDA's CRL, MRNA RSV Jab Study Succeeds

by Kinjel Shah

FDA gives CRL to Lilly's (LLY) Alzheimer's candidate, donanemab. Moderna's (MRNA) phase III study on its mRNA-based RSV vaccine candidate in older adults meets primary efficacy endpoints

Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea

by Zacks Equity Research

Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.